ATRA — Atara Biotherapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1604464 ·
Last close
$6.50
Market Cap
$66.22M
52W High
$19.15
52W Low
$3.92
ADV30
24,802
Next earnings
2026-11-10
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,224,000 959,000 -2,970,000 -2,229,000 18,607,000 4,055,000 56,509,000
Jun 2026 630,000 439,000 -4,720,000 -4,834,000 21,024,000 3,221,000 58,020,000
Mar 2026 516,000 392,000 -3,369,000 -4,145,000 19,997,000 8,360,000 57,309,000
Dec 2025 1,595,000 1,491,000 -2,563,000 -3,406,000 20,235,000 8,482,000 58,737,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-12,987,000
Investing CF
$2,647,000
Financing CF
$8,653,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.08
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,033,073,000
Inventory
$0
Receivables
$691,000
ST Investments
$5,862,000
EBIT TTM
$-12,698,000
Pretax Income TTM
$-14,613,000
Interest Exp TTM
$1,915,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,965,000
EBITDA
$838,000
Free Cash Flow
$-12,522,250
Enterprise Value
$77,012,600
Total Cash
$9,917,000
Total Debt
$8,482,000
Shares Out
10,188,438
Trailing EPS
$-1.12
Book Value
$-3.72
ROE
—
ROA
-0.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 120,772,000 35,862,000 32,688,000 20,235,000 58,737,000 -38,502,000 -50,940,000
Dec 2024 128,940,000 -83,438,000 -85,403,000 109,098,000 206,381,000 -97,283,000 -68,717,000
Dec 2023 8,573,000 -276,006,000 -276,126,000 165,504,000 264,735,000 -99,231,000 -192,977,000
Dec 2022 63,573,000 -280,513,000 -228,302,000 376,420,000 249,780,000 126,640,000 -270,430,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$-41,876,000
NetIncome TTM
$-16,688,000
OpCashFlow TTM
—
Assets (Latest)
$21,024,000
Forward EPS
$2.56

Peers — same industry

TickerNameMarket CapLastDaily %
CRDF Cardiff Oncology, Inc. $65.85M $0.85 —
AVXL ANAVEX LIFE SCIENCES CORP. $68.60M $0.74 —
CSBR CHAMPIONS ONCOLOGY, INC. $63.91M $4.59 —
VISK Viskase Holdings, Inc. $63.49M $4.43 —
NMRA Neumora Therapeutics, Inc. $62.85M $0.33 —

News headlines (Yahoo Finance, 1h cache)

Atara Biotherapeutics: Q3 Earnings Snapshot
2026-11-10 21:53 · Yahoo
Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress
2026-11-10 21:05 · Yahoo
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration
2026-10-14 12:05 · Yahoo
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
2026-09-30 12:05 · Yahoo
Atara Biotherapeutics Announces Changes to Its Board of Directors
2026-06-12 20:00 · Yahoo
FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive
2026-05-07 15:03 · Yahoo
Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise
2026-04-03 00:02 · Yahoo
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress
2026-08-12 20:05 · Yahoo
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
2026-04-01 12:01 · Yahoo
Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End
2026-06-17 20:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.